Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$244.61 USD

244.61
839,792

-0.39 (-0.16%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $244.56 -0.05 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 247)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Quest Diagnostics (DGX) Tops Q4 Earnings, Revenues Estimates

by Zacks Equity Research

Quest Diagnostics' (DGX) full year 2018 guidance is aligned with the company's long term outlook.

    Zacks Equity Research

    Quest Diagnostics to Buy MedXM, Boost Home Health Services

    by Zacks Equity Research

    Quest Diagnostics (DGX) actively pursues mergers and acquisitions to strengthen hold in the high-potential global home healthcare market.

      Zacks Equity Research

      What to Expect From Quest Diagnostics (DGX) in Q4 Earnings

      by Zacks Equity Research

      Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.

        Zacks Equity Research

        Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

        by Zacks Equity Research

        Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

          Zacks Equity Research

          Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS

          by Zacks Equity Research

          Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.

            Zacks Equity Research

            Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory

            by Zacks Equity Research

            Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.

              Zacks Equity Research

              Myriad Genetics Presents Encouraging EndoPredict Test Data

              by Zacks Equity Research

              Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.

                Zacks Equity Research

                Top Research Reports for Bank of America, Celgene & Goldman Sachs

                by Zacks Equity Research

                Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Celgene (CELG) and Goldman Sachs (GS).

                  Zacks Equity Research

                  Myriad Genetics (MYGN) Presents Positive riskScore Test Data

                  by Zacks Equity Research

                  Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.

                    Zacks Equity Research

                    Quest Diagnostics Banks on Buyouts to Expand in Diagnostic

                    by Zacks Equity Research

                    Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.